Recording of M4K Pharma’s Scientific Update Meeting – March 6th, 2019 Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join our live meetings. To find out when our next meeting will be, follow [...]
Richard Gold (McGill University) and Max Morgan (SGC, M4k Pharma) penned an opinion piece in the Globe and Mail discussing how open science projects with no patents can result in local economic development, citing the recent $1Billion investment deal that Celgene signed with the Ontario Institute for Cancer Research (OICR) and their commercialization arm FACIT [...]
Recording of M4K Pharma's Scientific Update Meeting - December 4th, 2018 Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. In this meeting, the team provides a comprehensive summary of the project accomplishments at the one year [...]
Recording of M4K Pharma's Scientific Update Meeting - November 6th, 2018. Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join the live meetings. To find out when our next meeting will be, follow [...]
Recording of M4K Pharma's Scientific Update Meeting - September 11th, 2018. Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join the live meetings. To find out when our next meeting will be, follow [...]
Recording of M4K Pharma's Scientific Update Meeting - August 15th, 2018. Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join the live meetings. To find out when our next meeting will be, follow [...]
Can an open drug discovery model find a solution for rare brain cancers in children? Dr. Aled Edwards OICR-funded drug discovery project’s unique ‘open science’ business model is accelerating the search for a solution to lethal pediatric brain cancers. Diffuse intrinsic pontine glioma (DIPG) is a lethal and inoperable brain cancer with a median survival [...]
Recording of M4K Pharma's Scientific Update Meeting - July 18th, 2018. Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join the live meetings. To find out when our next meeting will be, follow [...]
Recording of M4K Pharma's Scientific Update Meeting - June 6th, 2018. Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join the live meetings. To find out when our next meeting will be, follow [...]
Reaction Biology Joins the Fight Against DIPG with M4K Pharma [News Release] Malvern, PA- May 23, 2018. Reaction Biology Corporation (“RBC”), a leading contract research organization providing early stage drug discovery services, announced that it has partnered with M4K Pharma (“M4K”), an open science drug discovery and development company, in the fight against diffuse [...]
